Dabigatran 110 mg twice daily was associated with significantly lower major bleeding risk than rivaroxaban 15 mg (OR: 0.18; 95% CI: 0.04–0.76). Additionally, rivaroxaban 10 mg and edoxaban 15 mg ...

This analysis highlights the potential for tailoring anticoagulant therapy in elderly AF patients, with edoxaban 15 mg and rivaroxaban 10 mg emerging as promising options. However, results should be ...